NASDAQ · Biotechnology

REPL (REPL) Stock

$11.92 +0.08% NASDAQ: REPL Healthcare

Valuation

MetricValue
Price$11.92
Market Cap$1.00B
P/E Ratio-1.66
P/B Ratio1.01
P/S Ratio0.00
EPS (TTM)$-3.07
52-Week High$13.24
52-Week Low$1.50
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-59.37%
ROA-44.83%
ROCE-62.98%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.36
Current Ratio8.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-83.0M$-121.0M$-177.0M$-235.0M$-262.0M
Net Profit$-81.0M$-118.0M$-174.0M$-216.0M$-247.0M
EPS$-1.75$-2.26$-2.99$-3.24$-3.07
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$543.0M$461.0M$647.0M$488.0M$551.0M
Total Liabilities$44.0M$50.0M$91.0M$113.0M$135.0M
Cash$183.0M$106.0M$147.0M$74.0M$111.0M
Borrowings$33.0M$33.0M$61.0M$76.0M$76.0M

Latest News

BMO Capital Upgrades Replimune to Outperform From Underperform, Adjusts PT to $16 From $1 MT Newswires · Jun 30, 2026 Wedbush Lifts Price Target on Replimune to $9 From $6, Maintains Neutral Rating MT Newswires · Jun 29, 2026 Replimune's Fiscal Q4 Net Loss Narrows MT Newswires · Jun 29, 2026 Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update GlobeNewswire · Jun 29, 2026 JPMorgan Upgrades Replimune Group to Overweight From Neutral, $17 Price Target MT Newswires · Jun 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-61.0M$-82.0M$-128.0M$-185.0M$-192.0M
Investing Cash Flow$-191.0M$-4.0M$-145.0M$92.0M$-30.0M
Financing Cash Flow$97.0M$0$96.0M$0$97.0M
Net Cash Flow$123.0M$-77.0M$41.0M$-72.0M$37.0M
Free Cash Flow$-64.0M$-85.0M$-130.0M$-191.0M$-199.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-66.48%
Quick Ratio5.60
Interest Coverage-32.75
Return 1Y213.64%
Return 3Y-50.64%
Return 5Y-69.32%

Ownership

Insiders Held2.56%
Institutions Held95.37%
Institutions Float Held97.87%
Institutional HolderSharesReport Date
Baker Bros. Advisors, LP11,045,3362026-03-31
Price (T.Rowe) Associates Inc8,121,4332026-03-31
RTW Investments LP7,356,9162026-03-31
Blackrock Inc.6,239,2392026-03-31
Suvretta Capital Management, LLC4,221,8362026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARVN $8.02 -3.43% -6.94 $517.14M 0.00%
ATXSAstria Therapeutics, Inc. $12.58 +0.00% -7.40 $718.13M 0.00%
AVBP $30.84 -0.55% -8.82 $1.44B 0.00%
DNA $8.07 -0.19% -1.30 $527.50M 0.00%
IOVA $4.36 +1.04% -12.36 $1.95B 0.00%

About REPL

REPL is led by CEO Sushil Patel, employs 479 people, headquartered in US, publicly traded since 2018.

REPL stock trades at $11.92 with a market capitalization of $1.00B. The stock is valued at a price-to-earnings (P/E) ratio of -1.66, price-to-book of 1.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.50 and $13.24, and currently trades 10.0% below its 52-week high.

On profitability, REPL generates a return on equity (ROE) of -59.37%, return on capital employed of -62.98%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides